Polls Reveal Picks for Top Hematologic Oncology Abstracts at ASCO 2026

As the 2026 ASCO Annual Meeting approaches, excitement is mounting across the hematologic oncology community regarding data expected to shape future treatment paradigms in multiple myeloma, diffuse large B-cell lymphoma (DLBCL), myelofibrosis, and acute myeloid leukemia (AML). To better understand which presentations are generating the most anticipation, OncLive® conducted social media polls asking readers which hematologic malignancy subtype and which individual abstract they are most eager to see during the meeting.

Which hematologic malignancy subtype are you most excited to learn more about during the 2026 ASCO Annual Meeting?

• Multiple Myeloma
• DLBCL
• AML
• Myelofibrosis

Among respondents (n = 77), multiple myeloma emerged as the leading area of interest, receiving 43% of the vote. DLBCL followed at 26%, while AML a garnered 18%, and myelofibrosis accounted for 13%.

Which hematologic oncology abstract are you most looking forward to seeing during the 2026 ASCO Annual Meeting?

• LBA7000 frontMIND trial
• LBA6500 SENTRY trial
• LBA7506 SUCCESSOR-2 trial
• LBA7507 MajesTEC-9 trial

Interest in individual abstracts was evenly distributed among respondents (n = 12), with each study receiving 25% of the vote. The split reflects the broad range of potentially practice-changing data expected across lymphoma, myelofibrosis, and multiple myeloma presentations during the meeting.

Take a closer look at some of the most anticipated hematologic oncology abstracts scheduled to be presented during the 2026 ASCO Annual Meeting.

LBA7507: MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Presentation time: May 29, 2026, 4:57 pm CT

The phase 3 MajesTEC-9 trial (NCT05572515) is expected to provide key insight into whether teclistamab-cqyv (Tecvayli) can move earlier in the treatment sequence for patients with relapsed/refractory multiple myeloma. The study compared teclistamab monotherapy with standard PVd or Kd regimens in patients previously exposed to anti-CD38 therapy and lenalidomide. Investigators have already reported encouraging progression-free survival and overall survival findings, increasing anticipation around the upcoming full dataset. Clinicians are especially interested in understanding infection risk, safety considerations in community practice, and efficacy in high-risk disease subgroups.

LBA7506: Mezigdomide, carfilzomib, and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma: Results from the phase 3 SUCCESSOR-2 trial

Presentation time: May 29, 2026, 4:45 pm CT

The phase 3 SUCCESSOR-2 trial (NCT05552976) will evaluate whether the cereblon E3 ligase modulator mezigdomide can help overcome resistance to prior immunomodulatory therapies such as lenalidomide and pomalidomide. Investigators are hoping the study clarifies the future role of CELMoDs in the post-lenalidomide setting and whether the combination can address a growing unmet need for patients with relapsed/refractory multiple myeloma.

LBA6500: Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial

Presentation time: June 2, 2026, 9:45 am CT

The phase 3 SENTRY study (NCT04562389) evaluating selinexor (Xpovio) plus ruxolitinib (Jakafi) has generated significant discussion following a provocative topline press release. Although the trial reportedly demonstrated statistically significant improvements in spleen volume reduction, symptom improvement thresholds were not met. Investigators and clinicians alike are particularly eager to learn more about an unexpected overall survival signal observed in the study and whether the combination could ultimately alter frontline management strategies in myelofibrosis.

LBA7000: frontMIND: Phase 3 study of tafasitamab plus lenalidomide and R-CHOP for patients with newly diagnosed DLBCL

Presentation time: May 30, 2026, 3:00 pm CT

The phase 3 frontMIND study (NCT04824092) is anticipated to add to the rapidly evolving frontline DLBCL treatment landscape. The trial evaluated tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) in combination with rituximab (Rituxan) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for newly diagnosed disease. Experts have highlighted the study as a potential milestone in the ongoing expansion of frontline large B-cell lymphoma treatment options beyond standard R-CHOP-based therapy.